Ravichandran Ramasamy

Ravichandran Ramasamy

Auto-generated profile, based on publicly available information

Ravichandran Ramasamy

Diabetes Research Program, Department of Medicine, New York University Grossman School of Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Molecular Cell
Verified
Journal Article
Closed access
MGMinghui Gao
Minghui Gao
PMPrashant Monian
Prashant Monian
NQNosirudeen Quadri
Nosirudeen Quadri
RRRavichandran Ramasamy
Ravichandran Ramasamy
XJXuejun Jiang
Xuejun Jiang

10 March 2005 in Glycobiology
Verified
Journal Article
Open access
PDF file
RRRavichandran Ramasamy
Ravichandran Ramasamy
SVSusan J. Vannucci
Susan J. Vannucci
SYShirley Shi Du Yan
Shirley Shi Du Yan
KHKevan Herold
Kevan Herold
SYShi Fang Yan
Shi Fang Yan
ASAnn Marie Schmidt
Ann Marie Schmidt
The products of nonenzymatic glycation and oxidation of proteins and lipids, the advanced glycation end products (AGEs), accumulate in a wide variety of environments. AGEs may be generated rapidly or over long times stimulated by a range of distinct triggering mechanisms, thereby accounting for their roles in multiple settings and disease states. A critical property of AGEs is their ability to activate receptor for advanced glycation end products (RAGE), a signal transduction receptor of the immunoglobulin superfamily. It is our hypothesis that due to such interaction, AGEs impart a potent impact in tissues, stimulating processes linked to inflammation and its consequences. We hypothesize that AGEs cause perturbation in a diverse group of diseases, such as diabetes, inflammation, neurodegeneration, and aging. Thus, we propose that targeting this pathway may represent a logical step in the prevention/treatment of the sequelae of these disorders.

23 December 2011 in Annals of the New York Academy of Sciences
Verified
Journal Article
Open access
PDF file
RRRavichandran Ramasamy
Ravichandran Ramasamy
SYShi Fang Yan
Shi Fang Yan
ASAnn Marie Schmidt
Ann Marie Schmidt
The receptor for advanced glycation endproducts (RAGE) was first described as a signal transduction receptor for advanced glycation endproducts (AGEs), the products of nonenzymatic glycation and oxidation of proteins and lipids that accumulate in diabetes and in inflammatory foci. The discovery that RAGE was a receptor for inflammatory S100/calgranulins and high mobility group box 1 (HMGB1) set the stage for linking RAGE to both the consequences and causes of types 1 and 2 diabetes. Recent discoveries regarding the structure of RAGE as well as novel intracellular binding partner interactions advance our understanding of the mechanisms by which RAGE evokes pathological consequences and underscore strategies by which antagonism of RAGE in the clinic may be realized. Finally, recent data tracking RAGE in the clinic suggest that levels of soluble RAGEs and polymorphisms in the gene encoding RAGE may hold promise for the identification of patients who are vulnerable to the complications of diabetes and/or are receptive to therapeutic interventions designed to prevent and reverse the damage inflicted by chronic hyperglycemia, irrespective of its etiology.

12 December 2003 in Circulation Research
Verified
Journal Article
Closed access
SYShi Fang Yan
Shi Fang Yan
RRRavichandran Ramasamy
Ravichandran Ramasamy
YNYoshifumi Naka
Yoshifumi Naka
ASAnn Marie Schmidt
Ann Marie Schmidt
The cardiovascular complications of diabetes represent the leading cause of morbidity and mortality in affected subjects. The impact of hyperglycemia may be both direct and indirect: indirect consequences of elevated blood glucose lead to generation of advanced glycation endproducts, the products of nonenzymatic glycation/oxidation of proteins/lipids that accumulate in the vessel wall, and are signal transduction ligands for Receptor for AGE (RAGE). Although enhanced in diabetes, AGE accumulation also occurs in euglycemia and aging, albeit to lower degrees, driven by oxidant stress and inflammation. In hyperglycemia, production of 3-deoxyglucosone, at least in part via the polyol pathway, provides an amplification loop to sustain AGE generation, oxidant stress, and vascular activation. Furthermore, recruitment of inflammatory cells bearing S100/calgranulins, also ligands for RAGE, augments vascular dysfunction. We hypothesize that activation of RAGE is a final common pathway that transduces signals from these diverse biochemical and molecular species, leading to cardiovascular perturbation. Ultimately, these pathways synergize to construct a scaffold on which the complications of diabetes in the vasculature and heart may be built. We propose that antagonism of RAGE will provide a unique means to dismantle this scaffold and, thereby, suppress initiation/progression of vascular disease and cardiac dysfunction that accompany diabetes and aging.

11 March 2008 in Nature Clinical Practice Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
SYShi Fang Yan
Shi Fang Yan
RRRavichandran Ramasamy
Ravichandran Ramasamy
ASAnn Marie Schmidt
Ann Marie Schmidt

19 March 2010 in Circulation Research
Verified
Journal Article
Open access
PDF file
SYShi Fang Yan
Shi Fang Yan
RRRavichandran Ramasamy
Ravichandran Ramasamy
ASAnn Marie Schmidt
Ann Marie Schmidt
The immunoglobulin superfamily molecule RAGE (receptor for advanced glycation end product) transduces the effects of multiple ligands, including AGEs (advanced glycation end products), advanced oxidation protein products, S100/calgranulins, high-mobility group box-1, amyloid-β peptide, and β-sheet fibrils. In diabetes, hyperglycemia likely stimulates the initial burst of production of ligands that interact with RAGE and activate signaling mechanisms. Consequently, increased generation of proinflammatory and prothrombotic molecules and reactive oxygen species trigger further cycles of oxidative stress via RAGE, thus setting the stage for augmented damage to diabetic tissues in the face of further insults. Many of the ligand families of RAGE have been identified in atherosclerotic plaques and in the infarcted heart. Together with increased expression of RAGE in diabetic settings, we propose that release and accumulation of RAGE ligands contribute to exaggerated cellular damage. Stopping the vicious cycle of AGE-RAGE and RAGE axis signaling in the vulnerable heart and great vessels may be essential in controlling and preventing the consequences of diabetes.